121 related articles for article (PubMed ID: 10424513)
1. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections.
Amsden GW; Graci DM; Cabelus LJ; Hejmanowski LG
Chest; 1999 Jul; 116(1):115-9. PubMed ID: 10424513
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
3. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Noreddin AM; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
7. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Frémaux A; Sissia G; Geslin P
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Croisier D; Chavanet P; Lequeu C; Ahanou A; Nierlich A; Neuwirth C; Piroth L; Duong M; Buisson M; Portier H
J Antimicrob Chemother; 2002 Sep; 50(3):349-60. PubMed ID: 12205059
[TBL] [Abstract][Full Text] [Related]
9. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.
Vaudaux P; Francois P; Bisognano C; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 2002 May; 46(5):1503-9. PubMed ID: 11959588
[TBL] [Abstract][Full Text] [Related]
10. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Ambrose PG; Grasela DM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
[TBL] [Abstract][Full Text] [Related]
11. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
Bauernfeind A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Nicolau DP; Ambrose PG
Am J Med; 2001 Dec; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
Reinert RR; Lütticken R; Lemperle M; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():5-8. PubMed ID: 10404330
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae.
Kays MB; Conklin M
Pharmacotherapy; 2000 Nov; 20(11):1310-7. PubMed ID: 11079279
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
17. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR
Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
